Autoimmune stiff person syndrome and related myelopathies: Understanding of electrophysiological and immunological processes

Muscle and Nerve

Volumn 45, Issue 5, 2012, Pages 623-634

  Rakocevic, Goran ^a   Floeter, Mary Kay ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

Anti GAD antibodies; Autoimmunity; GABA; Paraneoplastic disorders; Stiff person syndrome

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID A RECEPTOR STIMULATING AGENT; AMPHIPHYSIN; AMPHIPHYSIN ANIBODY; AUTOANTIBODY; BACLOFEN; BENZODIAZEPINE DERIVATIVE; BOTULINUM TOXIN; DIAZEPAM; GEPHYRIN ANTIBODY; HLA DQ ANTIGEN; HLA DR ANTIGEN; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCLONAL ANTIBODY; NERVE PROTEIN; PLACEBO; PREDNISONE; RITUXIMAB; UNCLASSIFIED DRUG;

ALLELE; ANTIBODY PRODUCTION; ANTIBODY TITER; ASEPTIC MENINGITIS; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CLINICAL FEATURE; DISEASE ASSOCIATION; DROWSINESS; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; FATIGUE; GABAERGIC TRANSMISSION; HUMAN; IMMUNOGENETICS; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; MEMORY CELL; MOTONEURON; MUSCLE RIGIDITY; MUSCLE SPASM; NAUSEA; NERVE CELL MEMBRANE POTENTIAL; NERVOUS SYSTEM ELECTROPHYSIOLOGY; NEUROPATHOLOGY; NONHUMAN; PARANEOPLASTIC NEUROPATHY; PLASMAPHERESIS; PRESYNAPTIC NERVE; PRIORITY JOURNAL; REVIEW; SENSITIVITY ANALYSIS; SPINAL CORD DISEASE; STIFF MAN SYNDROME; STROKE; SYNAPTIC INHIBITION; UNSPECIFIED SIDE EFFECT; VOMITING;

AUTOANTIBODIES; ELECTROPHYSIOLOGY; GAMMA-AMINOBUTYRIC ACID; GLUTAMATE DECARBOXYLASE; HUMANS; SPINAL CORD DISEASES; STIFF-PERSON SYNDROME;

EID: 84859770153     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.23234     Document Type: Review

References (165)

1. Moersch FP, Woltman HW. Progressive fluctuating muscular rigidity and spasm ("stiff-man" syndrome); report of a case and some observations in 13 other cases. Proc Staff Meet Mayo Clin 1956; 31: 421-427.
2. Dalakas MC, Fujii M, Li M, McElroy B. The clinical spectrum of anti-GAD antibody-positive patients with stiff-person syndrome. Neurology 2000; 55: 1531-1535.
3. Levy LM, Dalakas MC, Floeter MK. The stiff-person syndrome: an autoimmune disorder affecting neurotransmission of gamma-aminobutyric acid. Ann Intern Med 1999; 131: 522-530.
4. Lorish TR, Thorsteinsson G, Howard FM Jr. Stiff-man syndrome updated. Mayo Clin Proc 1989; 64: 629-636.
5. McEvoy KM. Stiff-man syndrome. Semin Neurol 1991; 11: 197-205.
6. Toro C, Jacobowitz DM, Hallett M. Stiff-man syndrome. Semin Neurol 1994; 14: 154-158.
7. Meinck HM, Ricker K, Conrad B. The stiff-man syndrome: new pathophysiological aspects from abnormal exteroceptive reflexes and the response to clomipramine, clonidine, and tizanidine. J Neurol Neurosurg Psychiatry 1984; 47: 280-287.
8. Meinck HM, Ricker K, Hulser PJ, Schmid E, Peiffer J, Solimena M. Stiff man syndrome: clinical and laboratory findings in eight patients. J Neurol 1994; 241: 157-166.
9. Meinck HM, Ricker K, Hulser PJ, Solimena M. Stiff man syndrome: neurophysiological findings in eight patients. J Neurol 1995; 242: 134-142.
10. Grimaldi LM, Martino G, Braghi S, Quattrini A, Furlan R, Bosi E, et al. Heterogeneity of autoantibodies in stiff-man syndrome. Ann Neurol 1993; 34: 57-64.
11. Solimena M, Folli F, Aparisi R, Pozza G, De Camilli P. Autoantibodies to GABA-ergic neurons and pancreatic beta cells in stiff-man syndrome. N Engl J Med 1990; 322: 1555-1560.
12. Solimena M, Folli F, Denis-Donini S, Comi GC, Pozza G, De Camilli P, et al. Autoantibodies to glutamic acid decarboxylase in a patient with stiff-man syndrome, epilepsy, and type I diabetes mellitus. N Engl J Med 1988; 318: 1012-1020.
13. Dalakas MC, Li M, Fujii M, Jacobowitz DM. Stiff person syndrome: quantification, specificity, and intrathecal synthesis of GAD65 antibodies. Neurology 2001; 57: 780-784.
14. Ishizawa K, Komori T, Okayama K, Qin X, Kaneko K, Sasaki S, et al. Large motor neuron involvement in Stiff-man syndrome: a qualitative and quantitative study. Acta Neuropathol 1999; 97: 63-70.
15. Warich-Kirches M, von Bossanyi P, Treuheit T, Kirches E, Dietzmann K, Feistner H, et al. Stiff-man syndrome: possible autoimmune etiology targeted against GABA-ergic cells. Clin Neuropathol 1997; 16: 214-219.
16. Holmoy T, Skorstad G, Hestvik AL, Alvik KM, Vartdal F. Protective and detrimental immunity: lessons from stiff person syndrome and multiple sclerosis. Acta Neurol Scand Suppl 2009: 22-26.
17. Thompson PD. The stiff-man syndrome and related disorders. Parkinsonism Relat Disord 2001; 8: 147-153.
18. Warren JD, Scott G, Blumbergs PC, Thompson PD. Pathological evidence of encephalomyelitis in the stiff man syndrome with anti-GAD antibodies. J Clin Neurosci 2002; 9: 328-329.
19. Baekkeskov S, Aanstoot HJ, Christgau S, Reetz A, Solimena M, Cascalho M, et al. Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature 1990; 347: 151-156.
20. Butler MH, Solimena M, Dirkx R Jr, Hayday A, De Camilli P. Identification of a dominant epitope of glutamic acid decarboxylase (GAD-65) recognized by autoantibodies in stiff-man syndrome. J Exp Med 1993; 178: 2097-2106.
21. Ellis TM, Atkinson MA. The clinical significance of an autoimmune response against glutamic acid decarboxylase. Nat Med 1996; 2: 148-153.
22. Kim J, Namchuk M, Bugawan T, Fu Q, Jaffe M, Shi Y, et al. Higher autoantibody levels and recognition of a linear NH2-terminal epitope in the autoantigen GAD65, distinguish stiff-man syndrome from insulin-dependent diabetes mellitus. J Exp Med 1994; 180: 595-606.
23. Dinkel K, Meinck HM, Jury KM, Karges W, Richter W. Inhibition of gamma-aminobutyric acid synthesis by glutamic acid decarboxylase autoantibodies in stiff-man syndrome. Ann Neurol 1998; 44: 194-201.
24. Floeter MK, Valls-Sole J, Toro C, Jacobowitz D, Hallett M. Physiologic studies of spinal inhibitory circuits in patients with stiff-person syndrome. Neurology 1998; 51: 85-93.
25. Khasani S, Becker K, Meinck HM. Hyperekplexia and stiff-man syndrome: abnormal brainstem reflexes suggest a physiological relationship. J Neurol Neurosurg Psychiatry 2004; 75: 1265-1269.
26. Meinck HM, Thompson PD. Stiff man syndrome and related conditions. Mov Disord 2002; 17: 853-866.
27. Sandbrink F, Syed NA, Fujii MD, Dalakas MC, Floeter MK. Motor cortex excitability in stiff-person syndrome. Brain 2000; 123: 2231-2239.
28. Solimena M, Butler MH, De Camilli P. GAD, diabetes, and stiff-man syndrome: some progress and more questions. J Endocrinol Invest 1994; 17: 509-520.
29. Manto MU, Laute MA, Aguera M, Rogemond V, Pandolfo M, Honnorat J. Effects of anti-glutamic acid decarboxylase antibodies associated with neurological diseases. Ann Neurol 2007; 61: 544-551.
30. Raju R, Rakocevic G, Chen Z, Hoehn G, Semino-Mora C, Shi W, et al. Autoimmunity to GABAA-receptor-associated protein in stiff-person syndrome. Brain 2006; 129: 3270-3276.
31. De Camilli P, Thomas A, Cofiell R, Folli F, Lichte B, Piccolo G, et al. The synaptic vesicle-associated protein amphiphysin is the 128-kD autoantigen of stiff-man syndrome with breast cancer. J Exp Med 1993; 178: 2219-2223.
32. Dropcho EJ. Antiamphiphysin antibodies with small-cell lung carcinoma and paraneoplastic encephalomyelitis. Ann Neurol 1996; 39: 659-667.
33. Folli F. Stiff man syndrome, 40 years later. J Neurol Neurosurg Psychiatry 1998; 65: 618.
34. Yamamoto R, Li X, Winter S, Francke U, Kilimann MW. Primary structure of human amphiphysin, the dominant autoantigen of paraneoplastic stiff-man syndrome, and mapping of its gene (AMPH) to chromosome 7p13-p14. Hum Mol Genet 1995; 4: 265-268.
35. Yu Z, Kryzer TJ, Griesmann GE, Kim K, Benarroch EE, Lennon VA. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol 2001; 49: 146-154.
36. Butler MH, David C, Ochoa GC, Freyberg Z, Daniell L, Grabs D, et al. Amphiphysin II (SH3P9; BIN1), a member of the amphiphysin/Rvs family, is concentrated in the cortical cytomatrix of axon initial segments and nodes of Ranvier in brain and around T tubules in skeletal muscle. J Cell Biol 1997; 137: 1355-1367.
37. David C, Solimena M, De Camilli P. Autoimmunity in stiff-man syndrome with breast cancer is targeted to the C-terminal region of human amphiphysin, a protein similar to the yeast proteins, Rvs167 and Rvs161. FEBS Lett 1994; 351: 73-79.
38. Floyd S, Butler MH, Cremona O, David C, Freyberg Z, Zhang X, et al. Expression of amphiphysin I, an autoantigen of paraneoplastic neurological syndromes, in breast cancer. Mol Med 1998; 4: 29-39.
39. McCabe DJ, Turner NC, Chao D, Leff A, Gregson NA, Womersley HJ, et al. Paraneoplastic "stiff person syndrome" with metastatic adenocarcinoma and anti-Ri antibodies. Neurology 2004; 62: 1402-1404.
40. Nguyen-Huu BK, Urban PP, Schreckenberger M, Dieterich M, Werhahn KJ. Antiamphiphysin-positive stiff-person syndrome associated with small cell lung cancer. Mov Disord 2006; 21: 1285-1287.
41. Pittock SJ, Kryzer TJ, Lennon VA. Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome. Ann Neurol 2004; 56: 715-719.
42. Butler MH, Hayashi A, Ohkoshi N, Villmann C, Becker CM, Feng G, et al. Autoimmunity to gephyrin in Stiff-Man syndrome. Neuron 2000; 26: 307-312.
43. Rojas-Marcos I, Rousseau A, Keime-Guibert F, Rene R, Cartalat-Carel S, Delattre JY, et al. Spectrum of paraneoplastic neurologic disorders in women with breast and gynecologic cancer. Medicine (Baltimore) 2003; 82: 216-223.
44. Rosin L, DeCamilli P, Butler M, Solimena M, Schmitt HP, Morgenthaler N, et al. Stiff-man syndrome in a woman with breast cancer: an uncommon central nervous system paraneoplastic syndrome. Neurology 1998; 50: 94-98.
45. Saiz A, Dalmau J, Butler MH, Chen Q, Delattre JY, De Camilli P, et al. Anti-amphiphysin I antibodies in patients with paraneoplastic neurological disorders associated with small cell lung carcinoma. J Neurol Neurosurg Psychiatry 1999; 66: 214-217.
46. McHugh JC, Murray B, Renganathan R, Connolly S, Lynch T. GAD antibody positive paraneoplastic stiff person syndrome in a patient with renal cell carcinoma. Mov Disord 2007; 22: 1343-1346.
47. Saiz A, Blanco Y, Sabater L, Gonzalez F, Bataller L, Casamitjana R, et al. Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association. Brain 2008; 131: 2553-2563.
48. Espay AJ, Chen R. Rigidity and spasms from autoimmune encephalomyelopathies: stiff-person syndrome. Muscle Nerve 2006; 34: 677-690.
49. Vasconcelos OM, Dalakas MC. Stiff-person syndrome. Curr Treat Options Neurol 2003; 5: 79-90.
50. Ameli R, Snow J, Rakocevic G, Dalakas MC. A neuropsychological assessment of phobias in patients with stiff person syndrome. Neurology 2005; 64: 1961-1963.
51. Henningsen P, Meinck HM. Specific phobia is a frequent non-motor feature in stiff man syndrome. J Neurol Neurosurg Psychiatry 2003; 74: 462-465.
52. Rakocevic G, Raju R, Dalakas MC. Anti-glutamic acid decarboxylase antibodies in the serum and cerebrospinal fluid of patients with stiff-person syndrome: correlation with clinical severity. Arch Neurol 2004; 61: 902-904.
53. Barker RA, Revesz T, Thom M, Marsden CD, Brown P. Review of 23 patients affected by the stiff man syndrome: clinical subdivision into stiff trunk (man) syndrome, stiff limb syndrome, and progressive encephalomyelitis with rigidity. J Neurol Neurosurg Psychiatry 1998; 65: 633-640.
54. Gurol ME, Ertas M, Hanagasi HA, Sahin HA, Gursoy G, Emre M. Stiff leg syndrome: case report. Mov Disord 2001; 16: 1189-1193.
55. Saiz A, Graus F, Valldeoriola F, Valls-Sole J, Tolosa E. Stiff-leg syndrome: a focal form of stiff-man syndrome. Ann Neurol 1998; 43: 400-403.
56. Alberca R, Romero M, Chaparro J. Jerking stiff-man syndrome. J Neurol Neurosurg Psychiatry 1982; 45: 1159-1160.
57. Brown P, Marsden CD. The stiff man and stiff man plus syndromes. J Neurol 1999; 246: 648-652.
58. Nemni R, Braghi S, Natali-Sora MG, Lampasona V, Bonifacio E, Comi G, et al. Autoantibodies to glutamic acid decarboxylase in palatal myoclonus and epilepsy. Ann Neurol 1994; 36: 665-667.
59. Shaw PJ. Stiff-man syndrome and its variants. Lancet 1999; 353: 86-87.
60. Steffen H, Menger N, Richter W, Nolle B, Krastel H, Stayer C, et al. Immune-mediated retinopathy in a patient with stiff-man syndrome. Graefes Arch Clin Exp Ophthalmol 1999; 237: 212-219.
61. Fogan L. Progressive encephalomyelitis with rigidity responsive to plasmapheresis and immunosuppression. Ann Neurol 1996; 40: 451-453.
62. Giometto B, Miotto D, Faresin F, Argentiero V, Scaravilli T, Tavolato B. Anti-gabaergic neuron autoantibodies in a patient with stiff-man syndrome and ataxia. J Neurol Sci 1996; 143: 57-59.
63. Honnorat J, Saiz A, Giometto B, Vincent A, Brieva L, de Andres C, et al. Cerebellar ataxia with anti-glutamic acid decarboxylase antibodies: study of 14 patients. Arch Neurol 2001; 58: 225-230.
64. Abele M, Weller M, Mescheriakov S, Burk K, Dichgans J, Klockgether T. Cerebellar ataxia with glutamic acid decarboxylase autoantibodies. Neurology 1999; 52: 857-859.
65. Ishida K, Mitoma H, Song SY, Uchihara T, Inaba A, Eguchi S, et al. Selective suppression of cerebellar GABAergic transmission by an autoantibody to glutamic acid decarboxylase. Ann Neurol 1999; 46: 263-267.
66. Kono S, Miyajima H, Sugimoto M, Suzuki Y, Takahashi Y, Hishida A. Stiff-person syndrome associated with cerebellar ataxia and high glutamic acid decarboxylase antibody titer. Intern Med 2001; 40: 968-971.
67. Rakocevic G, Raju R, Semino-Mora C, Dalakas MC. Stiff person syndrome with cerebellar disease and high-titer anti-GAD antibodies. Neurology 2006; 67: 1068-1070.
68. Levy LM, Levy-Reis I, Fujii M, Dalakas MC. Brain gamma-aminobutyric acid changes in stiff-person syndrome. Arch Neurol 2005; 62: 970-974.
69. Armon C, McEvoy KM, Westmoreland BF, McManis PG. Clinical neurophysiologic studies in stiff-man syndrome: use of simultaneous video-electroencephalographic-surface electromyographic recording. Mayo Clin Proc 1990; 65: 960-967.
70. Cohen L. Stiff-man syndrome. Two patients treated with diazepam. JAMA 1966; 195: 222-224.
71. Howard FM Jr. A new and effective drug in the treatment of the stiff-man syndrome: preliminary report. Proc Staff Meet Mayo Clin 1963; 38: 203-212.
72. Meinck HM, Conrad B. Neuropharmacological investigations in the stiff-man syndrome. J Neurol 1986; 233: 340-347.
73. Molloy FM, Dalakas MC, Floeter MK. Increased brainstem excitability in stiff-person syndrome. Neurology 2002; 59: 449-451.
74. Matsumoto JY, Caviness JN, McEvoy KM. The acoustic startle reflex in stiff-man syndrome. Neurology 1994; 44: 1952-1955.
75. Berger C, Meinck HM. Head retraction reflex in stiff-man syndrome and related disorders. Mov Disord 2003; 18: 906-911.
76. Maddison P. Neuromyotonia. Clin Neurophysiol 2006; 117: 2118-2127.
77. Correale J, Garcia Erro M, Kosac S, Masci M, Fernandez Liguori N, Sica RE. An electrophysiological investigation of the "stiff-man" syndrome. Electromyogr Clin Neurophysiol 1988; 28: 215-221.
78. Poncelet AN. Blink reflexes and the silent period in tetanus. Muscle Nerve 2000; 23: 1435-1438.
79. Martinelli P, Nassetti S, Minardi C, Macri S, Ippoliti M. Electrophysiological evaluation of the stiff-man syndrome: further data. J Neurol 1996; 243: 551-553.
80. Ziemann U. Intracortical inhibition and facilitation in the conventional paired TMS paradigm. Electroencephalogr Clin Neurophysiol 1999; 51( suppl): 127-136.
81. Ziemann U, Chen R, Cohen LG, Hallett M. Dextromethorphan decreases the excitability of the human motor cortex. Neurology 1998; 51: 1320-1324.
82. Ziemann U. TMS and drugs. Clin Neurophysiol 2004; 115: 1717-1729.
83. Inghilleri M, Berardelli A, Marchetti P, Manfredi M. Effects of diazepam, baclofen and thiopental on the silent period evoked by transcranial magnetic stimulation in humans. Exp Brain Res 1996; 109: 467-472.
84. Ziemann U, Rothwell JC, Ridding MC. Interaction between intracortical inhibition and facilitation in human motor cortex. J Physiol 1996; 496: 873-881.
85. Di Lazzaro V, Pilato F, Oliviero A, Dileone M, Saturno E, Mazzone P, et al. Origin of facilitation of motor-evoked potentials after paired magnetic stimulation: direct recording of epidural activity in conscious humans. J Neurophysiol 2006; 96: 1765-1771.
86. Koerner C, Wieland B, Richter W, Meinck HM. Stiff-person syndromes: motor cortex hyperexcitability correlates with anti-GAD autoimmunity. Neurology 2004; 62: 1357-1362.
87. Rossi S, Ulivelli M, Malentacchi M, Greco G, Bartalini S, Borgogni P, et al. Effects of immunotherapy on motor cortex excitability in stiff person syndrome. J Neurol 2010; 257: 281-285.
88. Golden B, Levin L, Ban Y, Concepcion E, Greenberg DA, Tomer Y. Genetic analysis of families with autoimmune diabetes and thyroiditis: evidence for common and unique genes. J Clin Endocrinol Metab 2005; 90: 4904-4911.
89. Pugliese A, Solimena M, Awdeh ZL, Alper CA, Bugawan T, Erlich HA, et al. Association of HLA-DQB1*0201 with stiff-man syndrome. J Clin Endocrinol Metab 1993; 77: 1550-1553.
90. Alexopoulos H, Dalakas MC. A critical update on the immunopathogenesis of stiff person syndrome. Eur J Clin Invest 2010; 40: 1018-1025.
91. Dalakas MC. Stiff person syndrome: advances in pathogenesis and therapeutic interventions. Curr Treat Options Neurol 2009; 11: 102-110.
92. Edelhoff S, Grubin CE, Karlsen AE, Alder DA, Foster D, Disteche CM, et al. Mapping of glutamic acid decarboxylase (GAD) genes. Genomics 1993; 17: 93-97.
93. Solimena M, Aggujaro D, Muntzel C, Dirkx R, Butler M, De Camilli P, et al. Association of GAD-65, but not of GAD-67, with the Golgi complex of transfected Chinese hamster ovary cells mediated by the N-terminal region. Proc Natl Acad Sci USA 1993; 90: 3073-3077.
94. Alvarez FJ, Dewey DE, Harrington DA, Fyffe RE. Cell-type specific organization of glycine receptor clusters in the mammalian spinal cord. J Comp Neurol 1997; 379: 150-170.
95. Baer K, Waldvogel HJ, Faull RL, Rees MI. Localization of glycine receptors in the human forebrain, brainstem, and cervical spinal cord: an immunohistochemical review. Front Mol Neurosci 2009; 2: 25.
96. Waldvogel HJ, Baer K, Eady E, Allen KL, Gilbert RT, Mohler H, et al. Differential localization of gamma-aminobutyric acid type A and glycine receptor subunits and gephyrin in the human pons, medulla oblongata and uppermost cervical segment of the spinal cord: an immunohistochemical study. J Comp Neurol 2010; 518: 305-328.
97. Chen ZW, Olsen RW. GABAA receptor associated proteins: a key factor regulating GABAA receptor function. J Neurochem 2007; 100: 279-294.
98. Everitt AB, Luu T, Cromer B, Tierney ML, Birnir B, Olsen RW, Gage PW. Conductance of recombinant GABA (A) channels is increased in cells co-expressing GABA(A) receptor-associated protein. J Biol Chem 2004; 279: 21701-21706.
99. Solimena M, De Camilli P. Autoimmunity to glutamic acid decarboxylase (GAD) in stiff-man syndrome and insulin-dependent diabetes mellitus. Trends Neurosci 1991; 14: 452-457.
100. Meinck HM, Faber L, Morgenthaler N, Seissler J, Maile S, Butler M, et al. Antibodies against glutamic acid decarboxylase: prevalence in neurological diseases. J Neurol Neurosurg Psychiatry 2001; 71: 100-103.
101. Daw K, Ujihara N, Atkinson M, Powers AC. Glutamic acid decarboxylase autoantibodies in stiff-man syndrome and insulin-dependent diabetes mellitus exhibit similarities and differences in epitope recognition. J Immunol 1996; 156: 818-825.
102. Burbelo PD, Groot S, Dalakas MC, Iadarola MJ. High definition profiling of autoantibodies to glutamic acid decarboxylases GAD65/GAD67 in stiff-person syndrome. Biochem Biophys Res Commun 2008; 366: 1-7.
103. Lohmann T, Londei M, Hawa M, Leslie RD. Humoral and cellular autoimmune responses in stiff person syndrome. Ann NY Acad Sci 2003; 998: 215-222.
104. Schmidli RS, Colman PG, Bonifacio E. Disease sensitivity and specificity of 52 assays for glutamic acid decarboxylase antibodies. The Second International GADAB Workshop. Diabetes 1995; 44: 636-640.
105. Vianello M, Keir G, Giometto B, Betterle C, Tavolato B, Thompson EJ. Antigenic differences between neurological and diabetic patients with anti-glutamic acid decarboxylase antibodies. Eur J Neurol 2005; 12: 294-299.
106. Raju R, Foote J, Banga JP, Hall TR, Padoa CJ, Dalakas MC, et al. Analysis of GAD65 autoantibodies in stiff-person syndrome patients. J Immunol 2005; 175: 7755-7762.
107. Pugliese A, Brown D, Garza D, Murchison D, Zeller M, Redondo MJ, et al. Self-antigen-presenting cells expressing diabetes-associated autoantigens exist in both thymus and peripheral lymphoid organs. J Clin Invest 2001; 107: 555-564.
108. Hassin-Baer S, Kirson ED, Shulman L, Buchman AS, Bin H, Hindiyeh M, et al. Stiff-person syndrome following West Nile fever. Arch Neurol 2004; 61: 938-941.
109. Giometto B, Nicolao P, Macucci M, Tavolato B, Foxon R, Bottazzo GF. Temporal-lobe epilepsy associated with glutamic-acid-decarboxylase autoantibodies. Lancet 1998; 352: 457.
110. Kim JY, Chung EJ, Kim JH, Jung KY, Lee WY. Response to steroid treatment in anti-glutamic acid decarboxylase antibody-associated cerebellar ataxia, stiff person syndrome and polyendocrinopathy. Mov Disord 2006; 21: 2263-2264.
111. Vulliemoz S, Vanini G, Truffert A, Chizzolini C, Seeck M. Epilepsy and cerebellar ataxia associated with anti-glutamic acid decarboxylase antibodies. J Neurol Neurosurg Psychiatry 2007; 78: 187-189.
112. Peltola J, Kulmala P, Isojarvi J, Saiz A, Latvala K, Palmio J, et al. Autoantibodies to glutamic acid decarboxylase in patients with therapy-resistant epilepsy. Neurology 2000; 55: 46-50.
113. Vianello M, Bisson G, Dal Maschio M, Vassanelli S, Girardi S, Mucignat C, et al. Increased spontaneous activity of a network of hippocampal neurons in culture caused by suppression of inhibitory potentials mediated by anti-gad antibodies. Autoimmunity 2008; 41: 66-73.
114. Vianello M, Giometto B, Vassanelli S, Canato M, Betterle C, Mucignat C. Peculiar labeling of cultured hippocampal neurons by different sera harboring anti-glutamic acid decarboxylase autoantibodies (GAD-Ab). Exp Neurol 2006; 202: 514-518.
115. Antoine JC, Absi L, Honnorat J, Boulesteix JM, de Brouker T, Vial C, et al. Antiamphiphysin antibodies are associated with various paraneoplastic neurological syndromes and tumors. Arch Neurol 1999; 56: 172-177.
116. Pittock SJ, Lucchinetti CF, Parisi JE, Benarroch EE, Mokri B, Stephan CL, et al. Amphiphysin autoimmunity: paraneoplastic accompaniments. Ann Neurol 2005; 58: 96-107.
117. Takei K, Slepnev VI, Haucke V, De Camilli P. Functional partnership between amphiphysin and dynamin in clathrin-mediated endocytosis. Nat Cell Biol 1999; 1: 33-39.
118. Wigge P, McMahon HT. The amphiphysin family of proteins and their role in endocytosis at the synapse. Trends Neurosci 1998; 21: 339-344.
119. Kittler JT, Delmas P, Jovanovic JN, Brown DA, Smart TG, Moss SJ. Constitutive endocytosis of GABAA receptors by an association with the adaptin AP2 complex modulates inhibitory synaptic currents in hippocampal neurons. J Neurosci 2000; 20: 7972-7977.
120. Geis C, Weishaupt A, Hallermann S, Grunewald B, Wessig C, Wultsch T, et al. Stiff person syndrome-associated autoantibodies to amphiphysin mediate reduced GABAergic inhibition. Brain 2010; 133: 3166-3180.
121. Sommer C, Weishaupt A, Brinkhoff J, Biko L, Wessig C, Gold R, et al. Paraneoplastic stiff-person syndrome: passive transfer to rats by means of IgG antibodies to amphiphysin. Lancet 2005; 365: 1406-1411.
122. Fukunaga H, Engel AG, Lang B, Newsom-Davis J, Vincent A. Passive transfer of Lambert-Eaton myasthenic syndrome with IgG from man to mouse depletes the presynaptic membrane active zones. Proc Natl Acad Sci USA 1983; 80: 7636-7640.
123. Lang B, Newsom-Davis J, Prior C, Wray D. Antibodies to motor nerve terminals: an electrophysiological study of a human myasthenic syndrome transferred to mouse. J Physiol 1983; 344: 335-345.
124. Toyka KV, Drachman DB, Griffin DE, Pestronk A, Winkelstein JA, Fishbeck KH, et al. Myasthenia gravis. Study of humoral immune mechanisms by passive transfer to mice. N Engl J Med 1977; 296: 125-131.
125. Wessig C, Klein R, Schneider MF, Toyka KV, Naumann M, Sommer C. Neuropathology and binding studies in anti-amphiphysin-associated stiff-person syndrome. Neurology 2003; 61: 195-198.
126. Burns TM, Phillips LH II, Jones HR. Stiff person syndrome does not always occur with maternal passive transfer of GAD65 antibodies. Neurology 2005; 64: 399-400; author reply 399-400.
127. Nemni R, Caniatti LM, Gironi M, Bazzigaluppi E, De Grandis D. Stiff person syndrome does not always occur with maternal passive transfer of GAD65 antibodies. Neurology 2004; 62: 2101-2102.
128. Voltz R. Paraneoplastic neurological syndromes: an update on diagnosis, pathogenesis, and therapy. Lancet Neurol 2002; 1: 294-305.
129. Graus F, Saiz A, Dalmau J. Antibodies and neuronal autoimmune disorders of the CNS. J Neurol 2010; 257: 509-517.
130. McKeon A, Pittock SJ, Lennon VA. Stiff-person syndrome with amphiphysin antibodies: distinctive features of a rare disease. Neurology 2009; 73: 2132 [author reply 2133].
131. Murinson BB, Guarnaccia JB. Stiff-person syndrome with amphiphysin antibodies: distinctive features of a rare disease. Neurology 2008; 71: 1955-1958.
132. Toothaker TB, Rubin M. Paraneoplastic neurological syndromes: a review. Neurologist 2009; 15: 21-33.
133. Linke R, Schroeder M, Helmberger T, Voltz R. Antibody-positive paraneoplastic neurologic syndromes: value of CT and PET for tumor diagnosis. Neurology 2004; 63: 282-286.
134. Younes-Mhenni S, Janier MF, Cinotti L, Antoine JC, Tronc F, Cottin V, et al. FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes. Brain 2004; 127: 2331-2338.
135. Takenoshita H, Shizuka-Ikeda M, Mitoma H, Song S, Harigaya Y, Igeta Y, et al. Presynaptic inhibition of cerebellar GABAergic transmission by glutamate decarboxylase autoantibodies in progressive cerebellar ataxia. J Neurol Neurosurg Psychiatry 2001; 70: 386-389.
136. Geis C, Beck M, Jablonka S, Weishaupt A, Toyka KV, Sendtner M, Sommer C. Stiff person syndrome associated anti-amphiphysin antibodies reduce GABA associated [Ca(2+)]i rise in embryonic motoneurons. Neurobiol Dis 2009; 36: 191-199.
137. Jonas P, Bischofberger J, Sandkuhler J. Corelease of two fast neurotransmitters at a central synapse. Science 1998; 281: 419-424.
138. Westblom U. Stiff-man syndrome and clonazepam. JAMA 1977; 237: 1930.
139. Miller F, Korsvik H. Baclofen in the treatment of stiff-man syndrome. Ann Neurol 1981; 9: 511-512.
140. Olafson RA, Mulder DW, Howard FM. "Stiff-man" syndrome: a review of the literature, report of three additional cases and discussion of pathophysiology and therapy Mayo Clin Proc 1964; 39: 131-144.
141. Vermeij FH, van Doorn PA, Busch HF. Improvement of stiff-man syndrome with vigabatrin. Lancet 1996; 348( 9027): 612.
142. Silbert PL, Matsumoto JY, McManis PG, Stolp-Smith KA, Elliott BA, McEvoy KM. Intrathecal baclofen therapy in stiff-man syndrome: a double-blind, placebo-controlled trial. Neurology 1995; 45: 1893-1897.
143. Seitz RJ, Blank B, Kiwit JC, Benecke R. Stiff-person syndrome with anti-glutamic acid decarboxylase autoantibodies: complete remission of symptoms after intrathecal baclofen administration. J Neurol 1995; 242: 618-622.
144. Brashear HR, Phillips LH II. Autoantibodies to GABAergic neurons and response to plasmapheresis in stiff-man syndrome. Neurology 1991; 41: 1588-1592.
145. Harding AE, Thompson PD, Kocen RS, Batchelor JR, Davey N, Marsden CD. Plasma exchange and immunosuppression in the stiff man syndrome. Lancet 1989; 2: 915.
146. Vicari AM, Folli F, Pozza G, Comi GC, Comola M, Canal N, et al. Plasmapheresis in the treatment of stiff-man syndrome. N Engl J Med 1989; 320: 1499.
147. Dalakas MC. The role of IVIg in the treatment of patients with stiff person syndrome and other neurological diseases associated with anti-GAD antibodies. J Neurol 2005; 252( suppl 1): I19-25.
148. Gerschlager W, Brown P. Effect of treatment with intravenous immunoglobulin on quality of life in patients with stiff-person syndrome. Mov Disord 2002; 17: 590-593.
149. Karlson EW, Sudarsky L, Ruderman E, Pierson S, Scott M, Helfgott SM. Treatment of stiff-man syndrome with intravenous immune globulin. Arthritis Rheum 1994; 37: 915-918.
150. Khanlou H, Eiger G. Long-term remission of refractory stiff-man syndrome after treatment with intravenous immunoglobulin. Mayo Clin Proc 1999; 74: 1231-1232.
151. Dalakas MC, Fujii M, Li M, Lutfi B, Kyhos J, McElroy B. High-dose intravenous immune globulin for stiff-person syndrome. N Engl J Med 2001; 345: 1870-1876.
152. Dalakas MC. The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile. Pharmacol Ther 2004; 102: 177-193.
153. Dalakas MC, Clark WM. Strokes, thromboembolic events, and IVIg: rare incidents blemish an excellent safety record. Neurology 2003; 60: 1736-1737.
154. Dalakas MC. Invited article: inhibition of B cell functions: implications for neurology. Neurology 2008; 70: 2252-2260.
155. Bacorro EA, Tehrani R. Stiff-person syndrome: persistent elevation of glutamic acid decarboxylase antibodies despite successful treatment with rituximab. J Clin Rheumatol 2010; 16: 237-239.
156. Baker MR, Das M, Isaacs J, Fawcett PR, Bates D. Treatment of stiff person syndrome with rituximab. J Neurol Neurosurg Psychiatry 2005; 76: 999-1001.
157. Dupond JL, Essalmi L, Gil H, Meaux-Ruault N, Hafsaoui C. Rituximab treatment of stiff-person syndrome in a patient with thymoma, diabetes mellitus and autoimmune thyroiditis. J Clin Neurosci 2010; 17: 389-391.
158. Katoh N, Matsuda M, Ishii W, Morita H, Ikeda S. Successful treatment with rituximab in a patient with stiff-person syndrome complicated by dysthyroid ophthalmopathy. Intern Med 2010; 49: 237-241.
159. Dalakas M, Rakocevic G, Salajegheh M, Dambrosia JM, Hahn AF, Raju R, et al. Placebo-controlled trial of rituximab in anti-myelin-associated glycoprotein demyelinating neuropathy. Ann Neurol 2009; 65: 286-293.
160. Rizzi M, Knoth R, Hampe CS, Lorenz P, Gougeon ML, Lemercier B, et al. Long-lived plasma cells and memory B cells produce pathogenic anti-GAD65 autoantibodies in stiff person syndrome. PLoS One 2010; 5: e10838.
161. Jarius S, Stich O, Speck J, Rasiah C, Wildemann B, Meinck HM, et al. Qualitative and quantitative evidence of anti-glutamic acid decarboxylase-specific intrathecal antibody synthesis in patients with stiff person syndrome. J Neuroimmunol 2010; 229: 219-224.
162. Hanninen A, Soilu-Hanninen M, Hampe CS, Deptula A, Geubtner K, Ilonen J, et al. Characterization of CD4+ T cells specific for glutamic acid decarboxylase (GAD65) and proinsulin in a patient with stiff-person syndrome but without type 1 diabetes. Diabetes Metab Res Rev 2010; 26: 271-279.
163. Burton AR, Baquet Z, Eisenbarth GS, Tisch R, Smeyne R, Workman CJ, et al. Central nervous system destruction mediated by glutamic acid decarboxylase-specific CD4+ T cells. J Immunol 2010; 184: 4863-4870.
164. Skorstad G, Hestvik AL, Vartdal F, Holmoy T. Cerebrospinal fluid T cell responses against glutamic acid decarboxylase 65 in patients with stiff person syndrome. J Autoimmun 2009; 32: 24-32.
165. Holmoy T, Skorstad G, Roste LS, Scheie D, Alvik K. Stiff person syndrome associated with lower motor neuron disease and infiltration of cytotoxic T cells in the spinal cord. Clin Neurol Neurosurg 2009; 111: 708-712.